The role of tazemetostat in relapsed/refractory follicular lymphoma Review
| Authors: | von Keudell, G.; Salles, G. |
| Review Title: | The role of tazemetostat in relapsed/refractory follicular lymphoma |
| Abstract: | Large strides have been made in the treatment of follicular lymphoma (FL) over the last few years. Although the majority of patients respond to upfront therapy, many experience disease progression with a progressive shortening of subsequent treatment free intervals. New treatment options are therefore crucial for such patients. Tazemetostat is a first-in-class, selective, oral inhibitor of enhancer of zester homolog 2 (EZH2), a histone methyltransferase that is mutated in about a quarter of FL cases. Tazemetostat was recently approved for the treatment of patients with relapsed FL after 2 or more prior lines of therapy in the presence of an EZH2 mutation and for those without any other available therapeutic option, independently of EZH2 mutation status. In this review, we will summarize the background and key data that led to the development of tazemetostat, and, ultimately, to its approval for this indication. © The Author(s), 2021. |
| Keywords: | clinical trial; targeted therapy; follicular lymphoma; epigenetic; enhancer of zester homologue 2 (ezh2) |
| Journal Title: | Therapeutic Advances in Hematology |
| Volume: | 12 |
| ISSN: | 2040-6207 |
| Publisher: | Sage Publications |
| Date Published: | 2021-05-27 |
| Language: | English |
| DOI: | 10.1177/20406207211015882 |
| PROVIDER: | scopus |
| PMCID: | PMC8165870 |
| PUBMED: | 34104370 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 July 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
54Von Keudell -
269Salles
Related MSK Work